Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells
Purpose: Teduglutide is the first and only FDA-approved drug for long-term treatment of short bowel syndrome (SBS). The current study aimed to present an approach for production of teduglutide using recombinant DNA technology. Methods: The coding gene for teduglutide was cloned into pGEX-2T vector,...
Main Authors: | Ali Akbar Alizadeh, Saba Rasouli, Omid Jamshidi Kandjani, Salar Hemmati, Siavoush Dastmalchi |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2023-07-01
|
Series: | Advanced Pharmaceutical Bulletin |
Subjects: | |
Online Access: | https://apb.tbzmed.ac.ir/PDF/apb-13-592.pdf |
Similar Items
-
Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide—9 Years of Follow-Up
by: Zuzanna Zaczek, et al.
Published: (2022-04-01) -
Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications
by: Daniel Sungku Rim, et al.
Published: (2023-08-01) -
Teduglutide in amyloidosis‐associated intestinal failure
by: Clara Luhn, et al.
Published: (2023-08-01) -
Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure—A Nested Matched Pair Real-World Study
by: Elisabeth Blüthner, et al.
Published: (2023-04-01) -
Teduglutide therapy in a child with short bowel syndrome
by: Stojšić Mirjana, et al.
Published: (2023-01-01)